Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lothar R Pilz

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
International Journal of Clinical Pharmacology and Therapeutics|December 24, 2011
Adaptive randomization procedures for the web-based randomization system RANDI2Daniel Schrimpf, Lothar R Pilz
Onkologie|June 14, 2008
[Data documentation and data management with guidelines, experiences, caveats, and recommendations]Lutz Edler, Lothar R Pilz
International Journal of Clinical Pharmacology and Therapeutics|December 25, 2012
Design of clinical studies: adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC)Daniel Schrimpf, Christian Manegold, Lothar R Pilz
Translational Lung Cancer Research|March 26, 2015
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?Lothar R Pilz, Christian Manegold, Gerald Schmid-Bindert
Expert Review of Anticancer Therapy|September 19, 2009
Pemetrexed for the treatment of non-small-cell lung cancerChristian Manegold, Gerald Schmid-Bindert, Lothar R Pilz
Proteomics. Clinical Applications|March 12, 2014
Multiplex profiling of tumor-associated proteolytic activity in serum of colorectal cancer patientsDiego Yepes, Victor Costina, Lothar R Pilz, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|October 26, 2013
Steady state vascular imaging with extracellular gadobutrol: evaluation of the additional diagnostic benefit in patients who have undergone a peripheral magnetic resonance angiography protocolMelissa M Ong, Katharina Hausotter, Lothar R Pilz, et al.
Biomed Research International|June 14, 2013
Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinibBernd Kasper, Antonia Dimitrakopoulou-Strauss, Lothar R Pilz, et al.
Journal of Surgical Oncology|March 13, 2014
Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resectionJens Jakob, Per-Ulf Tunn, Andrew J Hayes, et al.
Onkologie|November 7, 2013
Characteristics, treatment and prognostic factors of patients with gynaecological malignancies treated in a palliative care unit at a university hospitalSamantha Aeckerle, Marina Moor, Lothar R Pilz, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
International Journal of Clinical Pharmacology and Therapeutics|December 24, 2011
Adaptive randomization procedures for the web-based randomization system RANDI2Daniel Schrimpf, Lothar R Pilz
Onkologie|June 14, 2008
[Data documentation and data management with guidelines, experiences, caveats, and recommendations]Lutz Edler, Lothar R Pilz
International Journal of Clinical Pharmacology and Therapeutics|December 25, 2012
Design of clinical studies: adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC)Daniel Schrimpf, Christian Manegold, Lothar R Pilz
Translational Lung Cancer Research|March 26, 2015
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?Lothar R Pilz, Christian Manegold, Gerald Schmid-Bindert
Expert Review of Anticancer Therapy|September 19, 2009
Pemetrexed for the treatment of non-small-cell lung cancerChristian Manegold, Gerald Schmid-Bindert, Lothar R Pilz
Proteomics. Clinical Applications|March 12, 2014
Multiplex profiling of tumor-associated proteolytic activity in serum of colorectal cancer patientsDiego Yepes, Victor Costina, Lothar R Pilz, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|October 26, 2013
Steady state vascular imaging with extracellular gadobutrol: evaluation of the additional diagnostic benefit in patients who have undergone a peripheral magnetic resonance angiography protocolMelissa M Ong, Katharina Hausotter, Lothar R Pilz, et al.
Biomed Research International|June 14, 2013
Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinibBernd Kasper, Antonia Dimitrakopoulou-Strauss, Lothar R Pilz, et al.
Journal of Surgical Oncology|March 13, 2014
Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resectionJens Jakob, Per-Ulf Tunn, Andrew J Hayes, et al.
Onkologie|November 7, 2013
Characteristics, treatment and prognostic factors of patients with gynaecological malignancies treated in a palliative care unit at a university hospitalSamantha Aeckerle, Marina Moor, Lothar R Pilz, et al.
Pageof 3